Klivira
Request demo

Navigating Emgality Prior Authorization in Dermatology Practice

While Emgality (galcanezumab) is primarily indicated for migraine prevention and cluster headache, understanding prior authorization dynamics in dermatology is crucial for practices managing a wide range of specialty medications and procedures.

Revenue cycle directors and prior authorization coordinators in dermatology face unique challenges, particularly with high-volume biologics and specialty procedures. Efficiently managing prior authorizations for these treatments is critical to patient access and financial health, demanding robust systems to navigate complex payer policies and documentation requirements.

Emgality's Context within Dermatology Prior Authorization

Emgality (galcanezumab) is an anti-CGRP monoclonal antibody indicated for the preventive treatment of migraine and episodic cluster headache. While it is a high-volume prior authorization target across various payer types, its therapeutic area does not typically intersect with primary dermatology indications like psoriasis, atopic dermatitis, or hidradenitis suppurativa. However, dermatology practices frequently manage patients with comorbidities, necessitating a broad understanding of specialty drug PA processes.

High-Volume Prior Authorization Categories in Dermatology

  • Biologics for psoriasis and psoriatic arthritis (e.g., TNF inhibitors, IL-17/23 inhibitors, oral targeted therapies)
  • Biologics for atopic dermatitis (e.g., dupilumab, tralokinumab, oral JAK inhibitors)
  • Biologics for hidradenitis suppurativa (e.g., adalimumab, secukinumab)
  • Mohs micrographic surgery for non-melanoma skin cancers in cosmetically sensitive areas
  • Advanced skin cancer treatments (e.g., immunotherapy for advanced melanoma)
  • Phototherapy, particularly when self-administered home therapy is prescribed

Key Documentation Requirements for Dermatology PAs

  • Diagnosis confirmation with severity scores (e.g., PASI, BSA for psoriasis; EASI, SCORAD for atopic dermatitis)
  • Documentation of prior topical, phototherapy, or conventional systemic therapy trials
  • Pre-biologic screenings (e.g., TB, hepatitis) and age-appropriate criteria
  • For Mohs surgery, details on site, tumor type, and conformance with AAD Appropriate Use Criteria
  • Distinction between clinic-administered and home self-administered treatments

Common Prior Authorization Denial Reasons in Dermatology

  • Failure to document required step therapy for biologics (e.g., prior topicals, phototherapy, methotrexate)
  • Insufficient documentation of disease severity (e.g., missing PASI, EASI, BSA scores)
  • Non-conformance of Mohs surgery indications with Appropriate Use Criteria
  • Gaps in pre-biologic screening documentation (e.g., TB, hepatitis)
  • Payer-mandated biosimilar substitution not addressed

Klivira's Automation for Dermatology Prior Authorization

Klivira's platform is engineered to streamline the complex prior authorization workflows inherent to dermatology practices. By integrating with EMRs and payer portals, Klivira automates critical steps, reducing manual burden and accelerating approvals. Our system incorporates AAD-guideline-aware step-therapy logic for psoriasis and atopic dermatitis biologics, AUC validation for Mohs surgery, and manages periodic re-authorization cycles for chronic treatments.

Frequently asked questions

Does Klivira specifically handle Emgality prior authorizations?

Yes, Klivira processes prior authorizations for a wide range of specialty medications, including Emgality, across all therapeutic areas where it is prescribed. Our platform connects to payer portals and utilizes X12 278 and ePA standards to manage the submission and tracking of these requests efficiently.

How does Klivira address the periodic re-authorization for chronic dermatological conditions?

Klivira automates the tracking and submission of periodic re-authorizations for chronic biologic treatments common in dermatology. The platform flags upcoming re-authorization dates, prompts for necessary updated clinical documentation, and facilitates timely resubmissions to prevent treatment interruptions.

Can Klivira help with prior authorization for Mohs surgery?

Absolutely. Klivira incorporates logic for Mohs micrographic surgery, including validation against Appropriate Use Criteria. Our system helps ensure that documentation regarding tumor type, site, and medical necessity aligns with payer policies, reducing the likelihood of denials.

What clinical guidelines does Klivira reference for dermatology PAs?

Klivira's platform integrates logic informed by major clinical guidelines relevant to dermatology, such as those from the American Academy of Dermatology (AAD) for psoriasis and atopic dermatitis, and NCCN guidelines for skin cancers. This helps ensure submissions meet evidence-based criteria.

How does Klivira manage step therapy requirements for dermatological biologics?

Klivira's system is designed to guide users through payer-specific step therapy requirements for dermatological biologics. It identifies necessary prior treatment trials (e.g., topicals, phototherapy, conventional systemics) and prompts for their documentation, ensuring compliance before submission.

Related coverage

Other emgality prior authorization by payer

Other emgality prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo